Questions | Groups | p-value* | |
---|---|---|---|
Panelists before brainstorming n (%) | Affiliated breast surgeons n (%) | ||
Q09. Following BCS and when the SLN is affected at upfront surgery, in addition to systemic treatment would you recommend: | |||
Axillary dissection? | 1 (3.7) | 47 (22.0)a | 0.02 |
Watchful waiting? | 4 (14.8)a | 11 (5.1) | |
Radiotherapy? | 22 (81.5) | 156 (72.9) | |
Q10. In a patient submitted to mastectomy with positive SLN at upfront surgery, in addition to systemic treatment what would you recommend: | |||
Axillary dissection? | 4 (14.8) | 86 (40.2) | 0.03 |
Watchful waiting? | 1 (3.7) | 9 (4.2) | |
Radiotherapy? | 22 (81.5) | 119 (55.6) | |
Q20. In T1/2 N0 patients submitted to mastectomy, evaluation of flap thickness using imaging should be recommended following surgery. | |||
I agree | 2 (7.4) | 68 (31.8) | 0.01 |
I disagree | 25 (92.6) | 146 (68.2) | |
Q24. In T1/2 N1 patients submitted to mastectomy who have achieved pCR following neoadjuvant treatment, radiotherapy of the thoracic wall should be recommended. | |||
I agree | 27 (100.0) | 140 (65.4) | 0.01 |
I disagree | 0 (0.0) | 74 (34.6) | |
Q36. In patients with the BRCA germline mutation, the use of platinum agents in neoadjuvant treatment should be recommended. | |||
I agree | 16 (59.3) | 175 (81.8) | 0.01 |
I disagree | 11 (40.7) | 39 (18.2) | |
Q37. In patients who will be submitted to neoadjuvant treatment, the addition of immunotherapy should be recommended as routine. | |||
I agree | 14 (51.9) | 65 (30.4) | 0.02 |
I disagree | 13 (48.1) | 149 (69.6) | |
Q38. In patients who will be submitted to neoadjuvant treatment, PD-L1 status should be taken into consideration when recommending immunotherapy. | |||
I agree | 13 (48.1) | 151 (70.6) | 0.02 |
I disagree | 14 (51.9) | 63 (29.4) | |
Q39. BRCA status should play a role in the decision regarding whether to recommend neoadjuvant treatment with immunotherapy. | |||
I agree | 5 (18.5) | 94 (43.9) | 0.01 |
I disagree | 22 (81.5) | 120 (56.1) | |
Q43. In patients with no BRCA germline mutation submitted to neoadjuvant therapy with immunotherapy and in whom there is residual disease, the use of adjuvant immunotherapy associated with capecitabine should be suggested. | |||
I agree | 14 (51.9) | 160 (74.8) | 0.01 |
I disagree | 13 (48.1) | 54 (25.2) |